ANI Pharmaceuticals Posts Strong First Quarter 2026 Results, Raises Financial Guidance
Ani Pharmaceuticals, Inc. reported a robust first quarter 2026 performance, driven by strong growth across its rare disease and generics businesses. The company's total net revenues increased 20% year-over-year to $275.1 million, while adjusted EBITDA grew 24% to $71.4 million.
The company cited the success of its lead rare disease asset, Cortrophin Gel, as a key factor in its quarterly growth. Cortrophin Gel net revenues reached $75.1 million for the first quarter, up 42% year-over-year and consistent with expectations. The product's fundamentals remain strong, with clear traction across target indications and accelerating momentum in new patient starts and monthly volumes dispensed.
ANI Pharmaceuticals also highlighted its progress in expanding its rare disease organization to capture the sizable opportunity in acute gouty arthritis flares by targeting podiatry and primary care. The company has recently hired and onboarded a dedicated commercial team, which will be in the field in the second quarter, further positioning it for growth.
Looking ahead, ANI Pharmaceuticals raised its 2026 financial guidance for total revenue to $1.08 billion-$1.14 billion and adjusted EBITDA to $285 million-$300 million. The company's President and Chief Executive Officer, Nikhil Lalwani, expressed his encouragement with the strong first quarter performance, which positions it well to drive meaningful growth in 2026 and beyond.
"I'm highly encouraged by our first quarter performance, which positions us well to drive meaningful growth in 2026 and beyond," said Nikhil Lalwani. "Our team has worked tirelessly to execute against our top priorities for 2026, and I'm proud of the progress we've made."
The company's strong quarterly results reflect its ability to adapt to changing market conditions and capitalize on emerging trends in the pharmaceutical industry.
